Lek Business Results in the first nine months of 2006

24. 10. 2006

Ljubljana, October 24 – Lek, a Sandoz company, part of Novartis’ generics business, posted very successful results in the first nine months of 2006. It recorded sales of SIT 119 bn, which is 26 percentage higher than the same period last year. Lek’s share of Sandoz sales was 14,3%.

Lek d.d. once again posted its highest sales figures in pharmaceutical products (prescription medicines), at SIT 95 bn, with OTC medicines accounting for SIT 14 bn. Lek’s other programs amounted to SIT 9 bn.

Slovenia accounted for 7.6%, Central and Eastern Europe 49.5%, and Western Europe, the USA and Overseas Countries accounted for 42.9% of total sales. Lek’s leading market in the first nine months of 2006 was the Russian Federation, which also posted the highest sales growth with nearly 42 percent.

The leading product in the first nine months of 2006 was Amoxiclav, which is a global product with respect to the number of markets and sales routes. It was followed by Ketonal (analgesic and antirheumatic drug), Omeprazol (for the treatment of gastro-intestinal disorders, particularly duodenal and gastric ulcers) and Linex (antidiarrheal and antiflatulent capsules).


Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biopharmaceutical products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz’s global markets. Lek d.d. employs about 2,850 people and achieved total sales of USD 656,5 million in 2005. For further information please consult http://www.lek.si

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 600 active substances in over 5 000 forms worldwide. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (U.S.) and sells its products in more than 110 countries. In 2005, Sandoz employed around 20,000 people worldwide and posted sales of USD 4.7 billion

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2005, the Group’s businesses achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Approximately USD 4.8 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 91,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

For further information contact:
Špela Jurak
Corporate Communications
Lek Pharmaceuticals d.d.

Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32